



## Corporate Profile

### Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,890,000 individuals worldwide. Through its network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 210,191 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

## Growth Strategy

### GOAL 10...

...is the name of Fresenius Medical Care's strategy adopted by 2005 for sustained growth until 2010. In order to achieve revenues of US-\$ 12 billion in 2010 in conjunction with an annual revenue growth of 7 - 9% based on constant currencies and an annual 10% increase in net income, GOAL 10 defines four strategic paths:

- Organic growth in dialysis services by innovative treatment techniques and the opening of new clinics
- Acquisitions of existing clinics to ensure optimized international presence
- Horizontal expansion in the sector of Renal Drugs as well as
- A boosted activity in home therapies


## Key Figures - Summary Third Quarter 2010

Net revenue	US-\$	3,058 million	+ 6%
Operating income (EBIT)	US-\$	493 million	+ 9%
Net income attributable to Fresenius Medical Care AG & Co. KGaA	US-\$	248 million	+ 10%
Earnings per share	US-\$	0.82	+ 9%
Total assets <sup>1)</sup>	US-\$	16,696 million	
Operating Cash flow	US-\$	384 million	
Employees <sup>1)</sup>		72,812	
Patients <sup>1)</sup>		210,191	+ 9%
Clinics <sup>1)</sup>		2,716	+ 8%
Treatments <sup>2)</sup>		23,41 million	+ 7%

<sup>1)</sup> as of September 30, 2010

<sup>2)</sup> first nine months of 2010

### Revenue Q3 2010 per region (US\$ 3,058 m)



### Goals for 2010

Net revenue	>US-\$ 12.0 billion
Net income	US-\$ 960-980 million
Leverage Ratio (Debt/EBITDA)	< 2.5
Capital Expenditures	US-\$ 550-650 million
Acquisitions	up to US-\$ 500 million

## Management Board

- Dr. Ben J. Lipps (Chairman)
- Rice Powell (Vice Chairman)
- Michael Brosnan
- Roberto Fusté
- Dr. Emanuele Gatti
- Dr. Rainer Runte
- Kent Wanzek

## Supervisory Board

- Dr. Gerd Krick (Chairman)
- Dr. Dieter Schenk (Vice Chairman)
- Dr. Walter L. Weisman
- John Gerhard Kringel
- William P. Johnston
- Prof. Dr. Bernd Fahrholz



## Share Profile – Key Data

## Ticker Symbols

Frankfurt Stock Exchange
New York Stock Exchange (NYSE)
Reuters: XETRA / Frankfurt Stock Exchange
Bloomberg

## Ordinary shares

FME
FMS
FMEG.DE / FMEG.F
FME GY

## Preference shares

FME3
FMS/P
FMEG_p.DE / FMEG_p.F
FME3 GY

## Security Identification Numbers

WKN
ISIN
CUSIP No. (NYSE)

578 580	578 583
DE 0005785802	DE 0005785836
358029106	358029205


## Financing Instruments and Maturity Profile

	Year issued	Amount in million	Coupon %	Maturity
Credit Agreement Term Loan A	2006	\$ 1,850 <sup>1)</sup>		March 31, 2013
Credit Agreement Term Loan B	2006	\$ 1,750 <sup>1)</sup>		March 31, 2013
Senior Notes 2010 - 2016	2010	€ 250	5 1/2%	July 15, 2016
Senior Notes 2007 - 2017	2007	\$ 500	6 7/8%	July 15, 2017
Trust Preferred Securities IV	2001	\$ 225	7 7/8%	June 15, 2011
Trust Preferred Securities V	2001	€ 300	7 3/8%	June 15, 2011
Notes (Schuldscheindarlehen)	2009	€ 155		October 27, 2012
Notes (Schuldscheindarlehen)	2009	€ 45		October 27, 2014

<sup>1)</sup> at the beginning before amortisation and extension

## Share Price Development last 12 months

in €



## Financial Calendar

Event	Date
<b>Report on Third Quarter</b>	
Earnings Release:	November 2, 2010
Conference Call:	November 2, 2010
Deutsche Börse & IFRS Filing:	November 30, 2010
<b>Report on Full Year 2010:</b>	February 23, 2011
<b>Report on First Quarter 2011:</b>	May 4, 2011
<b>Annual General Meeting 2011:</b>	May 12, 2011
<b>Report on Second Quarter 2011:</b>	August 2, 2011
<b>Report on Third Quarter 2011:</b>	November 2, 2011

## Capital Structure

## Overview

Ordinary Shares	~ 36%	~ 64%	297.99 m shares
Preference Shares	100%		3.93 m shares
	Fresenius SE	Free Float	

## Contacts

Fresenius Medical Care AG & Co. KGaA  
Investor Relations & Corporate Communications  
Else-Kröner-Straße 1 61352 Bad Homburg

**Oliver Maier** P: +49(0)6172-609-2525  
Senior Vice President, F: +49(0)6172-609-2301  
Head of IR & CC

**Gerrit Jost** P: +49(0)6172-609-5216  
Director

## North America

**Terry L. Morris** P: +1-800-948-2538  
Vice President F: +1-615-345-5605